Hikma receives approval for Phenylephrine HCl Injection, USP

London, 7 January 2013 – Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (“Hikma”), the fast growing multinational pharmaceutical group, today announces the approval of its New Drug Application (NDA) for Phenylephrine HCl Injection, USP, 10mg/mL, 1mL vial by the US Food and Drug Administration (FDA).

Press Release Product 13 January 2013

Hikma’s Phenylephrine is indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation, in such settings as septic shock or anesthesia. This NDA has been approved under Section 505(b)(2) of the US Federal Food Drug and Cosmetic Act and it is the only FDA-approved version of Phenylephrine HCl Injection, USP.

Said Darwazah, CEO of Hikma, said, “This approval demonstrates our strong regulatory capabilities and the successful execution of our strategy to develop a more differentiated injectable product portfolio."

According to IMS Health, sales of Phenylephrine Injection in the US market were approximately $14 million for the 12 months ending November 2012.

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.